Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options

Acinetobacter baumannii is undoubtedly one of the most successful pathogens responsible for hospital-acquired nosocomial infections in the modern healthcare system. Due to the prevalence of infections and outbreaks caused by multi-drug resistant A. baumannii, few antibiotics are effective for treating infections caused by this pathogen. To overcome this problem, knowledge of the pathogenesis and antibiotic resistance mechanisms of A. baumannii is important. In this review, we summarize current studies on the virulence factors that contribute to A. baumannii pathogenesis, including porins, capsular polysaccharides, lipopolysaccharides, phospholipases, outer membrane vesicles, metal acquisition systems, and protein secretion systems. Mechanisms of antibiotic resistance of this organism, including acquirement of β-lactamases, up-regulation of multidrug efflux pumps, modification of aminoglycosides, permeability defects, and alteration of target sites, are also discussed. Lastly, novel prospective treatment options for infections caused by multi-drug resistant A. baumannii are summarized.

[1]  P. Courvalin,et al.  First Detection of GES-5 Carbapenemase-Producing Acinetobacter baumannii Isolate. , 2017, Microbial drug resistance.

[2]  Mostafizur Rahman,et al.  Antimicrobial Resistance Mechanisms and Genetic Diversity of Multidrug-Resistant Acinetobacter baumannii Isolated from a Teaching Hospital in Malaysia. , 2017, Microbial drug resistance.

[3]  J. Mateos,et al.  The FhaB/FhaC two-partner secretion system is involved in adhesion of Acinetobacter baumannii AbH12O-A2 strain , 2017, Virulence.

[4]  P. Rather,et al.  An ompR-envZ Two-Component System Ortholog Regulates Phase Variation, Osmotic Tolerance, Motility, and Virulence in Acinetobacter baumannii Strain AB5075 , 2016, Journal of bacteriology.

[5]  R. Pathania,et al.  Fosfomycin resistance in Acinetobacter baumannii is mediated by efflux through a major facilitator superfamily (MFS) transporter—AbaF , 2017, The Journal of antimicrobial chemotherapy.

[6]  C. Landersdorfer,et al.  High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii , 2017, The Journal of antimicrobial chemotherapy.

[7]  M. Salem,et al.  Investigation of the Virulence Factors and Molecular Characterization of the Clonal Relations of Multidrug-Resistant Acinetobacter baumannii Isolates. , 2017, Journal of AOAC International.

[8]  M. Provinciali,et al.  Colistin enhances therapeutic efficacy of daptomycin or teicoplanin in a murine model of multiresistant Acinetobacter baumannii sepsis. , 2016, Diagnostic microbiology and infectious disease.

[9]  A. S. Attia,et al.  The secretome of Acinetobacter baumannii ATCC 17978 type II secretion system reveals a novel plasmid encoded phospholipase that could be implicated in lung colonization. , 2016, International journal of medical microbiology : IJMM.

[10]  S. Kuo,et al.  In vitro activity of SecA inhibitors in combination with carbapenems against carbapenem-hydrolysing class D β-lactamase-producing Acinetobacter baumannii. , 2016, The Journal of antimicrobial chemotherapy.

[11]  C. Landersdorfer,et al.  Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii. , 2016, International journal of antimicrobial agents.

[12]  A. Tsakris,et al.  First report of an NDM-1 metallo-β-lactamase-producing Acinetobacter baumannii clinical isolate in Greece. , 2016, International journal of antimicrobial agents.

[13]  Łukasz Nierzwicki,et al.  Correlation between the number of Pro-Ala repeats in the EmrA homologue of Acinetobacter baumannii and resistance to netilmicin, tobramycin, imipenem and ceftazidime. , 2016, Journal of global antimicrobial resistance.

[14]  C. Rumbo,et al.  Assessment of antivirulence activity of several d-amino acids against Acinetobacter baumannii and Pseudomonas aeruginosa. , 2016, The Journal of antimicrobial chemotherapy.

[15]  M. Kempf,et al.  First case of OXA-24-producing Acinetobacter baumannii in cattle from Reunion Island, France. , 2016, International journal of antimicrobial agents.

[16]  R. Schmidt,et al.  Iron-Regulated Phospholipase C Activity Contributes to the Cytolytic Activity and Virulence of Acinetobacter baumannii , 2016, PloS one.

[17]  V. Nizet,et al.  Classical β-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii , 2016, Antimicrobial Agents and Chemotherapy.

[18]  Crhisllane Rafaele dos Santos Vasconcelos,et al.  High Frequency of OXA-253-Producing Acinetobacter baumannii in Different Hospitals in Recife, Brazil , 2016, Antimicrobial Agents and Chemotherapy.

[19]  Devin K Schweppe,et al.  In vivo protein interaction network analysis reveals porin-localized antibiotic inactivation in Acinetobacter baumannii strain AB5075 , 2016, Nature Communications.

[20]  M. Kempf,et al.  Wide spread of OXA-23-producing carbapenem-resistant Acinetobacter baumannii belonging to clonal complex II in different hospitals in Lebanon. , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[21]  Xiaofen Liu,et al.  Synergistic killing by meropenem and colistin combination of carbapenem-resistant Acinetobacter baumannii isolates from Chinese patients in an in vitro pharmacokinetic/pharmacodynamic model. , 2016, International journal of antimicrobial agents.

[22]  Neang S. Ly,et al.  Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies. , 2016, The Journal of antimicrobial chemotherapy.

[23]  Sander K. Govers,et al.  ‘Artilysation’ of endolysin λSa2lys strongly improves its enzymatic and antibacterial activity against streptococci , 2016, Scientific Reports.

[24]  I. Kusradze,et al.  Characterization and Testing the Efficiency of Acinetobacter baumannii Phage vB-GEC_Ab-M-G7 as an Antibacterial Agent , 2016, Front. Microbiol..

[25]  Eric P. Skaar,et al.  Acinetobacter baumannii Coordinates Urea Metabolism with Metal Import To Resist Host-Mediated Metal Limitation , 2016, mBio.

[26]  W. Wongpoowarak,et al.  Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii , 2016, Antimicrobial Agents and Chemotherapy.

[27]  D. Bumann,et al.  A Novel Genome-Editing Platform for Drug-Resistant Acinetobacter baumannii Reveals an AdeR-Unrelated Tigecycline Resistance Mechanism , 2016, Antimicrobial Agents and Chemotherapy.

[28]  Marion J. Skalweit,et al.  Bulgecin A as a β-lactam enhancer for carbapenem-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii clinical isolates containing various resistance mechanisms , 2016, Drug design, development and therapy.

[29]  Amjad Ali,et al.  Pangenome and immuno-proteomics analysis of Acinetobacter baumannii strains revealed the core peptide vaccine targets , 2016, BMC Genomics.

[30]  S. Koren,et al.  Diversity in a Polymicrobial Community Revealed by Analysis of Viromes, Endolysins and CRISPR Spacers , 2016, PloS one.

[31]  S. Sitthisak,et al.  Enhanced Antibacterial Activity of Acinetobacter baumannii Bacteriophage ØABP-01 Endolysin (LysABP-01) in Combination with Colistin , 2016, Front. Microbiol..

[32]  S. Choi,et al.  In Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii , 2016, Antimicrobial Agents and Chemotherapy.

[33]  Neang S. Ly,et al.  Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii. , 2016, International journal of antimicrobial agents.

[34]  D. Muthusamy,et al.  Invitro Activities of Polymyxins and Rifampicin against Carbapenem Resistant Acinetobacter baumannii at a Tertiary Care Hospital from South India. , 2016, Journal of clinical and diagnostic research : JCDR.

[35]  K. Walia,et al.  Molecular Characterization of Invasive Carbapenem-Resistant Acinetobacter baumannii from a Tertiary Care Hospital in South India , 2016, Infectious Diseases and Therapy.

[36]  A. Tsakris,et al.  In Vitro Bactericidal Activity of Trimethoprim-Sulfamethoxazole Alone and in Combination with Colistin against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates , 2016, Antimicrobial Agents and Chemotherapy.

[37]  M. V. van Hoek,et al.  Peptides from American alligator plasma are antimicrobial against multi-drug resistant bacterial pathogens including Acinetobacter baumannii , 2016, BMC Microbiology.

[38]  H. Balkhy,et al.  High prevalence of the PER-1 gene among carbapenem-resistant Acinetobacter baumannii in Riyadh, Saudi Arabia , 2016, European Journal of Clinical Microbiology & Infectious Diseases.

[39]  K. Schulze,et al.  Acinetobacter baumannii phenylacetic acid metabolism influences infection outcome through a direct effect on neutrophil chemotaxis , 2016, Proceedings of the National Academy of Sciences.

[40]  Iraida E. Robledo,et al.  Genetic environment of the KPC gene in Acinetobacter baumannii ST2 clone from Puerto Rico and genomic insights into its drug resistance. , 2016, Journal of medical microbiology.

[41]  T. Naas,et al.  First Occurrence of OXA-72-Producing Acinetobacter baumannii in Serbia , 2016, Antimicrobial Agents and Chemotherapy.

[42]  HasaniAlka,et al.  Frequency of Aminoglycoside-Modifying Enzymes and ArmA Among Different Sequence Groups of Acinetobacter baumannii in Iran , 2016 .

[43]  Xiaojiao Zhang,et al.  Mucosal immunization with purified OmpA elicited protective immunity against infections caused by multidrug-resistant Acinetobacter baumannii. , 2016, Microbial pathogenesis.

[44]  Clonal spread of blaOXA-72-carrying Acinetobacter baumannii sequence type 512 in Taiwan. , 2016, International journal of antimicrobial agents.

[45]  Y. Cong,et al.  Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model , 2016, PloS one.

[46]  C. Ryu,et al.  Combination therapy with polymyxin B and netropsin against clinical isolates of multidrug-resistant Acinetobacter baumannii , 2016, Scientific Reports.

[47]  A. Flieger,et al.  Bacterial Sphingomyelinases and Phospholipases as Virulence Factors , 2016, Microbiology and Molecular Reviews.

[48]  Young Bae Kim,et al.  Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection Methods , 2016, Front. Microbiol..

[49]  Eric P. Skaar,et al.  The Response of Acinetobacter baumannii to Zinc Starvation. , 2016, Cell host & microbe.

[50]  G. Traglia,et al.  Serum Albumin and Ca2+ Are Natural Competence Inducers in the Human Pathogen Acinetobacter baumannii , 2016, Antimicrobial Agents and Chemotherapy.

[51]  C. McElheny,et al.  In Vitro Activity of Fusidic Acid-Containing Combinations against Carbapenem-Resistant Acinetobacter baumannii Clinical Strains , 2016, Antimicrobial Agents and Chemotherapy.

[52]  W. Jeng,et al.  Single amino acid substitution Gly186Val in AdeS restores tigecycline susceptibility of Acinetobacter baumannii. , 2016, The Journal of antimicrobial chemotherapy.

[53]  T. Naas,et al.  GES-11-producing Acinetobacter baumannii clinical isolates from Tunisian hospitals: Long-term dissemination of GES-type carbapenemases in North Africa. , 2016, Journal of global antimicrobial resistance.

[54]  Y. Chen,et al.  Abrp, a new gene, confers reduced susceptibility to tetracycline, glycylcine, chloramphenicol and fosfomycin classes in Acinetobacter baumannii , 2016, European Journal of Clinical Microbiology & Infectious Diseases.

[55]  T. Umland,et al.  The Response Regulator BfmR Is a Potential Drug Target for Acinetobacter baumannii , 2016, mSphere.

[56]  J. Pachón,et al.  Efficacy of Lysophosphatidylcholine in Combination with Antimicrobial Agents against Acinetobacter baumannii in Experimental Murine Peritoneal Sepsis and Pneumonia Models , 2016, Antimicrobial Agents and Chemotherapy.

[57]  C. Ryu,et al.  In Vivo Application of Bacteriophage as a Potential Therapeutic Agent To Control OXA-66-Like Carbapenemase-Producing Acinetobacter baumannii Strains Belonging to Sequence Type 357 , 2016, Applied and Environmental Microbiology.

[58]  T. Parish,et al.  Synergy between Colistin and the Signal Peptidase Inhibitor MD3 Is Dependent on the Mechanism of Colistin Resistance in Acinetobacter baumannii , 2016, Antimicrobial Agents and Chemotherapy.

[59]  Karl A. Hassan,et al.  Rapid multiplexed phenotypic screening identifies drug resistance functions for three novel efflux pumps in Acinetobacter baumannii. , 2016, The Journal of antimicrobial chemotherapy.

[60]  P. Zipfel,et al.  CipA of Acinetobacter baumannii Is a Novel Plasminogen Binding and Complement Inhibitory Protein. , 2016, The Journal of infectious diseases.

[61]  J. Mazucheli,et al.  Strategies for the treatment of polymyxin B-resistant Acinetobacter baumannii infections. , 2016, International journal of antimicrobial agents.

[62]  S. Jang,et al.  Development and Evaluation of Species-Specific PCR for Detection of Nine Acinetobacter Species. , 2016, Annals of clinical and laboratory science.

[63]  S. Kuo,et al.  In Vivo and In Vitro Efficacy of Minocycline-Based Combination Therapy for Minocycline-Resistant Acinetobacter baumannii , 2016, Antimicrobial Agents and Chemotherapy.

[64]  B. Fu,et al.  Characterization of surface antigen protein 1 (SurA1) from Acinetobacter baumannii and its role in virulence and fitness. , 2016, Veterinary microbiology.

[65]  Mohit Kumar Identification of a Novel NDM Variant, blaNDM-3, From a Multidrug-Resistant Acinetobacter baumannii , 2016, Infection Control & Hospital Epidemiology.

[66]  K. Ko,et al.  High rate of colistin dependence in Acinetobacter baumannii. , 2016, The Journal of antimicrobial chemotherapy.

[67]  Brian T. Tsuji,et al.  Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii , 2016, Antimicrobial Agents and Chemotherapy.

[68]  Brian T. Tsuji,et al.  Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance , 2016, Antimicrobial Agents and Chemotherapy.

[69]  R. Bonomo,et al.  Mutations Decreasing Intrinsic β-Lactam Resistance Are Linked to Cell Division in the Nosocomial Pathogen Acinetobacter baumannii , 2016, Antimicrobial Agents and Chemotherapy.

[70]  J. Cooke How to minimise antibiotic resistance. , 2016, The Lancet. Infectious diseases.

[71]  X. Wang,et al.  Molecular characterization of carbapenemase genes in Acinetobacter baumannii in China. , 2016, Genetics and molecular research : GMR.

[72]  Sander K. Govers,et al.  Efficacy of Artilysin Art-175 against Resistant and Persistent Acinetobacter baumannii , 2016, Antimicrobial Agents and Chemotherapy.

[73]  Takashi Asahara,et al.  Protective Effect of a Synbiotic against Multidrug-Resistant Acinetobacter baumannii in a Murine Infection Model , 2016, Antimicrobial Agents and Chemotherapy.

[74]  You-ning Liu,et al.  Effects of Efflux Pump Inhibitors on Colistin Resistance in Multidrug-Resistant Gram-Negative Bacteria , 2016, Antimicrobial Agents and Chemotherapy.

[75]  Weiwei Huang,et al.  Immunization with a 22-kDa outer membrane protein elicits protective immunity to multidrug-resistant Acinetobacter baumannii , 2016, Scientific Reports.

[76]  Chad W. Euler,et al.  Novel Engineered Peptides of a Phage Lysin as Effective Antimicrobials against Multidrug-Resistant Acinetobacter baumannii , 2016, Antimicrobial Agents and Chemotherapy.

[77]  H. Barrios,et al.  A Multicenter Study in Mexico Finds Acinetobacter baumannii Clinical Isolates Belonging to Clonal Complexes 636B (113B) and 92B Harboring OXA-72, OXA-239, and OXA-469 , 2016, Antimicrobial Agents and Chemotherapy.

[78]  Eric P. Skaar,et al.  Medically Relevant Acinetobacter Species Require a Type II Secretion System and Specific Membrane-Associated Chaperones for the Export of Multiple Substrates and Full Virulence , 2016, PLoS pathogens.

[79]  M. Rahmati-Yamchi,et al.  Frequency of Aminoglycoside-Modifying Enzymes and ArmA Among Different Sequence Groups of Acinetobacter baumannii in Iran. , 2016, Microbial drug resistance.

[80]  Brent S. Weber,et al.  Pathogenic Acinetobacter: from the Cell Surface to Infinity and Beyond , 2015, Journal of bacteriology.

[81]  H. Wei,et al.  Antibacterial Activity of a Novel Peptide-Modified Lysin Against Acinetobacter baumannii and Pseudomonas aeruginosa , 2015, Front. Microbiol..

[82]  H. Mobley,et al.  Acinetobacter baumannii Is Dependent on the Type II Secretion System and Its Substrate LipA for Lipid Utilization and In Vivo Fitness , 2015, Journal of bacteriology.

[83]  M. Al-Haroni,et al.  Imipenem Treatment Induces Expression of Important Genes and Phenotypes in a Resistant Acinetobacter baumannii Isolate , 2015, Antimicrobial Agents and Chemotherapy.

[84]  I. Mitroulis,et al.  Immunomodulatory Role of Clarithromycin in Acinetobacter baumannii Infection via Formation of Neutrophil Extracellular Traps , 2015, Antimicrobial Agents and Chemotherapy.

[85]  M. McConnell,et al.  Lipopolysaccharide loss produces partial colistin dependence and collateral sensitivity to azithromycin, rifampicin and vancomycin in Acinetobacter baumannii. , 2015, International journal of antimicrobial agents.

[86]  L. Peterson,et al.  Joint Transcriptional Control of Virulence and Resistance to Antibiotic and Environmental Stress in Acinetobacter baumannii , 2015, mBio.

[87]  J. Barbé,et al.  Novobiocin Inhibits the Antimicrobial Resistance Acquired through DNA Damage-Induced Mutagenesis in Acinetobacter baumannii , 2015, Antimicrobial Agents and Chemotherapy.

[88]  V. Srinivasan,et al.  Functional Characterization of AbeD, an RND-Type Membrane Transporter in Antimicrobial Resistance in Acinetobacter baumannii , 2015, PloS one.

[89]  Y. Shamoo,et al.  Acinetobacter baumannii Repeatedly Evolves a Hypermutator Phenotype in Response to Tigecycline That Effectively Surveys Evolutionary Trajectories to Resistance , 2015, PloS one.

[90]  E. Mylonakis,et al.  Impact of a Cross-Kingdom Signaling Molecule of Candida albicans on Acinetobacter baumannii Physiology , 2015, Antimicrobial Agents and Chemotherapy.

[91]  J. Reymond,et al.  In Vitro Activity of the Novel Antimicrobial Peptide Dendrimer G3KL against Multidrug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa , 2015, Antimicrobial Agents and Chemotherapy.

[92]  Kelsey A. Gregg,et al.  A PmrB-Regulated Deacetylase Required for Lipid A Modification and Polymyxin Resistance in Acinetobacter baumannii , 2015, Antimicrobial Agents and Chemotherapy.

[93]  C. Vay,et al.  In vitro activity of minocycline alone or in combination in multidrug-resistant Acinetobacter baumannii isolates. , 2015, Journal of medical microbiology.

[94]  R. Relich,et al.  Antimicrobial Activity of Gallium Protoporphyrin IX against Acinetobacter baumannii Strains Displaying Different Antibiotic Resistance Phenotypes , 2015, Antimicrobial Agents and Chemotherapy.

[95]  A. Viale,et al.  Differential Role of the T6SS in Acinetobacter baumannii Virulence , 2015, PloS one.

[96]  I. Ebersberger,et al.  Acinetobacter baumannii Virulence Is Mediated by the Concerted Action of Three Phospholipases D , 2015, PloS one.

[97]  Ming-Hsien Chiang,et al.  Acinetobacter baumannii Extracellular OXA-58 Is Primarily and Selectively Released via Outer Membrane Vesicles after Sec-Dependent Periplasmic Translocation , 2015, Antimicrobial Agents and Chemotherapy.

[98]  J. Córdoba,et al.  In Vitro Activities of Novel Antimicrobial Combinations against Extensively Drug-Resistant Acinetobacter baumannii , 2015, Antimicrobial Agents and Chemotherapy.

[99]  Woojun Park,et al.  Synergistic Effect of Oleanolic Acid on Aminoglycoside Antibiotics against Acinetobacter baumannii , 2015, PloS one.

[100]  Yongrui Liu,et al.  Detection of AmpC β-lactamases in Acinetobacter baumannii in the Xuzhou region and analysis of drug resistance. , 2015, Experimental and therapeutic medicine.

[101]  C. Hou,et al.  Drug-resistant gene of blaOXA-23, blaOXA-24, blaOXA-51 and blaOXA-58 in Acinetobacter baumannii. , 2015, International journal of clinical and experimental medicine.

[102]  Jung Hun Lee,et al.  Quantitative proteomic view associated with resistance to clinically important antibiotics in Gram-positive bacteria: a systematic review , 2015, Front. Microbiol..

[103]  Jung Hun Lee,et al.  Urgent need for β-lactam-β-lactamase inhibitors. , 2015, The Lancet. Infectious diseases.

[104]  P. Zipfel,et al.  Translation Elongation Factor Tuf of Acinetobacter baumannii Is a Plasminogen-Binding Protein , 2015, PloS one.

[105]  S. Pukatzki,et al.  A multidrug resistance plasmid contains the molecular switch for type VI secretion in Acinetobacter baumannii , 2015, Proceedings of the National Academy of Sciences.

[106]  J. Picazo,et al.  Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii? , 2015, Antimicrobial Agents and Chemotherapy.

[107]  Ming-Feng Lin,et al.  The Role of the Two-Component System BaeSR in Disposing Chemicals through Regulating Transporter Systems in Acinetobacter baumannii , 2015, PloS one.

[108]  E. Santillana,et al.  Crystal Structure of Hcp from Acinetobacter baumannii: A Component of the Type VI Secretion System , 2015, PloS one.

[109]  Jie-ping Zhu,et al.  Biofilm Formation Caused by Clinical Acinetobacter baumannii Isolates Is Associated with Overexpression of the AdeFGH Efflux Pump , 2015, Antimicrobial Agents and Chemotherapy.

[110]  V. Tam,et al.  Risk factors for nephrotoxicity onset associated with polymyxin B therapy. , 2015, The Journal of antimicrobial chemotherapy.

[111]  Dao-jun Yu,et al.  In vitro and in vivo analysis of antimicrobial agents alone and in combination against multi-drug resistant Acinetobacter baumannii , 2015, Front. Microbiol..

[112]  J. Brodbelt,et al.  Reinforcing Lipid A Acylation on the Cell Surface of Acinetobacter baumannii Promotes Cationic Antimicrobial Peptide Resistance and Desiccation Survival , 2015, mBio.

[113]  D. Wareham,et al.  Colistin and Fusidic Acid, a Novel Potent Synergistic Combination for Treatment of Multidrug-Resistant Acinetobacter baumannii Infections , 2015, Antimicrobial Agents and Chemotherapy.

[114]  Jung Hun Lee,et al.  Structural Basis for Carbapenem-Hydrolyzing Mechanisms of Carbapenemases Conferring Antibiotic Resistance , 2015, International journal of molecular sciences.

[115]  Zhongdao Wu,et al.  Outer membrane vesicles isolated from two clinical Acinetobacter baumannii strains exhibit different toxicity and proteome characteristics. , 2015, Microbial pathogenesis.

[116]  Kazuaki Matsumoto,et al.  Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections. , 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[117]  Cary L. Honnold,et al.  Fatal outbreak of an emerging clone of extensively drug-resistant Acinetobacter baumannii with enhanced virulence. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[118]  R. Isberg,et al.  Antibiotic Modulation of Capsular Exopolysaccharide and Virulence in Acinetobacter baumannii , 2015, PLoS pathogens.

[119]  Y. Li,et al.  Clonal dissemination of extensively drug-resistant Acinetobacter baumannii producing an OXA-23 β-lactamase at a teaching hospital in Shanghai, China. , 2015, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[120]  A. Peleg,et al.  Acinetobacter baumannii: Evolution of Antimicrobial Resistance—Treatment Options , 2015, Seminars in Respiratory and Critical Care Medicine.

[121]  K. Ko,et al.  Effect of carbonyl cyanide 3-chlorophenylhydrazone (CCCP) on killing Acinetobacter baumannii by colistin , 2015, Journal of Microbiology.

[122]  M. Blokesch,et al.  The type VI secretion system of Vibrio cholerae fosters horizontal gene transfer , 2015, Science.

[123]  A. S. Attia,et al.  Acinetobacter baumannii universal stress protein A plays a pivotal role in stress response and is essential for pneumonia and sepsis pathogenesis. , 2015, International journal of medical microbiology : IJMM.

[124]  Y. Yu,et al.  Tigecycline resistance in Acinetobacter baumannii mediated by frameshift mutation in plsC, encoding 1-acyl-sn-glycerol-3-phosphate acyltransferase , 2015, European Journal of Clinical Microbiology & Infectious Diseases.

[125]  Ming-Feng Lin,et al.  Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside. , 2014, World journal of clinical cases.

[126]  BakourSofiane,et al.  Characterization of Acinetobacter baumannii Clinical Isolates Carrying blaOXA-23 Carbapenemase and 16S rRNA Methylase armA genes in Yemen , 2014 .

[127]  J. Rolain,et al.  Characterization of Acinetobacter baumannii clinical isolates carrying bla(OXA-23) carbapenemase and 16S rRNA methylase armA genes in Yemen. , 2014, Microbial drug resistance.

[128]  D. Ritchie,et al.  A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[129]  Ronald N. Jones,et al.  Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[130]  A. Chapeaurouge,et al.  Identification of immunogenic proteins of the bacterium Acinetobacter baumannii using a proteomic approach , 2014, Proteomics. Clinical applications.

[131]  M. Touchon,et al.  The Genomic Diversification of the Whole Acinetobacter Genus: Origins, Mechanisms, and Consequences , 2014, Genome biology and evolution.

[132]  C. Tang,et al.  Prevalence and mapping of a plasmid encoding a type IV secretion system in Acinetobacter baumannii. , 2014, Genomics.

[133]  Katherina C. Chua,et al.  Whole-Genome Sequence Analysis of the Naturally Competent Acinetobacter baumannii Clinical Isolate A118 , 2014, Genome biology and evolution.

[134]  N. Soares,et al.  The Acinetobacter baumannii Omp33-36 Porin Is a Virulence Factor That Induces Apoptosis and Modulates Autophagy in Human Cells , 2014, Infection and Immunity.

[135]  P. Dunman,et al.  Identification of Acinetobacter baumannii Serum-Associated Antibiotic Efflux Pump Inhibitors , 2014, Antimicrobial Agents and Chemotherapy.

[136]  Christian Cambillau,et al.  Architecture and assembly of the Type VI secretion system. , 2014, Biochimica et biophysica acta.

[137]  T. P. G. Chagas,et al.  Characterization of carbapenem-resistant Acinetobacter baumannii in Brazil (2008-2011): countrywide spread of OXA-23-producing clones (CC15 and CC79). , 2014, Diagnostic microbiology and infectious disease.

[138]  C. Tang,et al.  The sensor kinase BfmS mediates virulence in Acinetobacter baumannii. , 2014, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[139]  J. Cannon,et al.  The risk of seizures among the carbapenems: a meta-analysis. , 2014, The Journal of antimicrobial chemotherapy.

[140]  A. Peleg,et al.  A global virulence regulator in Acinetobacter baumannii and its control of the phenylacetic acid catabolic pathway. , 2014, The Journal of infectious diseases.

[141]  G. Volckaert,et al.  Engineered Endolysin-Based “Artilysins” To Combat Multidrug-Resistant Gram-Negative Pathogens , 2014, mBio.

[142]  Bin Chen,et al.  Immunization against Multidrug-Resistant Acinetobacter baumannii Effectively Protects Mice in both Pneumonia and Sepsis Models , 2014, PloS one.

[143]  G. Rossolini,et al.  Epidemic Diffusion of OXA-23-Producing Acinetobacter baumannii Isolates in Italy: Results of the First Cross-Sectional Countrywide Survey , 2014, Journal of Clinical Microbiology.

[144]  Chuanmin Tao,et al.  Efficacy and Safety of Polymyxins for the Treatment of Acinectobacter baumannii Infection: A Systematic Review and Meta-Analysis , 2014, PloS one.

[145]  Mark J. Mandel,et al.  Genome-Wide Identification of Acinetobacter baumannii Genes Necessary for Persistence in the Lung , 2014, mBio.

[146]  T. Kirikae,et al.  Dissemination of 16S rRNA Methylase ArmA-Producing Acinetobacter baumannii and Emergence of OXA-72 Carbapenemase Coproducers in Japan , 2014, Antimicrobial Agents and Chemotherapy.

[147]  Comparison of colistin–carbapenem, colistin–sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections , 2014, European Journal of Clinical Microbiology & Infectious Diseases.

[148]  Federico Perez,et al.  New Insights into Dissemination and Variation of the Health Care-Associated Pathogen Acinetobacter baumannii from Genomic Analysis , 2014, mBio.

[149]  Xi Li,et al.  Decreased susceptibility to tigecycline in Acinetobacter baumannii mediated by a mutation in trm encoding SAM-dependent methyltransferase. , 2014, The Journal of antimicrobial chemotherapy.

[150]  Ming-Feng Lin,et al.  Role of the BaeSR two-component system in the regulation of Acinetobacter baumannii adeAB genes and its correlation with tigecycline susceptibility , 2014, BMC Microbiology.

[151]  A. Akin,et al.  Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia , 2014, Infection.

[152]  J. Vila,et al.  Role of OmpA in the Multidrug Resistance Phenotype of Acinetobacter baumannii , 2013, Antimicrobial Agents and Chemotherapy.

[153]  Andrés Magán,et al.  Role of Acinetobacter baumannii UmuD Homologs in Antibiotic Resistance Acquired through DNA Damage-Induced Mutagenesis , 2013, Antimicrobial Agents and Chemotherapy.

[154]  Mayumi Yoshida,et al.  Successful treatment of skin and soft tissue infection due to carbapenem-resistant Acinetobacter baumannii by ampicillin-sulbactam and meropenem combination therapy. , 2013, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[155]  P. Nordmann,et al.  TEM-1 β-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii. , 2013, The Journal of antimicrobial chemotherapy.

[156]  D. Nicolau,et al.  In Vitro Pharmacodynamics of Polymyxin B and Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii , 2013, Antimicrobial Agents and Chemotherapy.

[157]  C. Taitt,et al.  Antimicrobial Resistance Determinants in Acinetobacter baumannii Isolates Taken from Military Treatment Facilities , 2013, Antimicrobial Agents and Chemotherapy.

[158]  J. Pachón,et al.  Association of the outer membrane protein Omp33 with fitness and virulence of Acinetobacter baumannii. , 2013, The Journal of infectious diseases.

[159]  A. Vicente,et al.  Carbapenem-resistant Acinetobacter baumannii from Brazil: role of carO alleles expression and blaOXA-23 gene , 2013, BMC Microbiology.

[160]  Jung Hun Lee,et al.  Lipid a biosynthesis of multidrug-resistant pathogens - a novel drug target. , 2013, Current pharmaceutical design.

[161]  J. Sheng,et al.  Molecular Epidemiology and Mechanisms of Tigecycline Resistance in Clinical Isolates of Acinetobacter baumannii from a Chinese University Hospital , 2013, Antimicrobial Agents and Chemotherapy.

[162]  A. di Caro,et al.  In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection. , 2013, Microbial drug resistance.

[163]  Nichollas E. Scott,et al.  A common pathway for O‐linked protein‐glycosylation and synthesis of capsule in Acinetobacter baumannii , 2013, Molecular microbiology.

[164]  Sang Hee Lee,et al.  Strategies to Minimize Antibiotic Resistance , 2013, International journal of environmental research and public health.

[165]  Je Chul Lee,et al.  Acinetobacter baumannii Outer Membrane Vesicles Elicit a Potent Innate Immune Response via Membrane Proteins , 2013, PloS one.

[166]  J. Mekalanos,et al.  PAAR-repeat proteins sharpen and diversify the Type VI secretion system spike , 2013, Nature.

[167]  B. Liu,et al.  Diversity in the Major Polysaccharide Antigen of Acinetobacter Baumannii Assessed by DNA Sequencing, and Development of a Molecular Serotyping Scheme , 2013, PloS one.

[168]  J. Vila,et al.  Globally Expanding Carbapenemase Finally Appears in Spain: Nosocomial Outbreak of Acinetobacter baumannii Producing Plasmid-Encoded OXA-23 in Barcelona, Spain , 2013, Antimicrobial Agents and Chemotherapy.

[169]  Jace W. Jones,et al.  Unique Structural Modifications Are Present in the Lipopolysaccharide from Colistin-Resistant Strains of Acinetobacter baumannii , 2013, Antimicrobial Agents and Chemotherapy.

[170]  Ming-Feng Lin,et al.  Molecular Epidemiology of Integron-Associated Antimicrobial Gene Cassettes in the Clinical Isolates of Acinetobacter baumannii from Northern Taiwan , 2013, Annals of laboratory medicine.

[171]  Kyudong Han,et al.  Co-existence of blaOXA-23 and armA in multidrug-resistant Acinetobacter baumannii isolated from a hospital in South Korea. , 2013, Journal of medical microbiology.

[172]  C. Landersdorfer,et al.  Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[173]  R. Hall,et al.  Variation in the Complex Carbohydrate Biosynthesis Loci of Acinetobacter baumannii Genomes , 2013, PloS one.

[174]  Y.-T. Lee,et al.  Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections , 2013, European Journal of Clinical Microbiology & Infectious Diseases.

[175]  G. Bou,et al.  Antimicrobial Resistance and Virulence: a Successful or Deleterious Association in the Bacterial World? , 2013, Clinical Microbiology Reviews.

[176]  R. Munson,et al.  Acinetobacter baumannii Utilizes a Type VI Secretion System for Bacterial Competition , 2013, PloS one.

[177]  R. Saha,et al.  Microbial siderophores: a mini review , 2013, Journal of basic microbiology.

[178]  M. McConnell,et al.  Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. , 2013, FEMS microbiology reviews.

[179]  C. Wolz,et al.  Opposing effects of aminocoumarins and fluoroquinolones on the SOS response and adaptability in Staphylococcus aureus. , 2013, The Journal of antimicrobial chemotherapy.

[180]  P. Higgins,et al.  OXA-235, a Novel Class D β-Lactamase Involved in Resistance to Carbapenems in Acinetobacter baumannii , 2013, Antimicrobial Agents and Chemotherapy.

[181]  J. Mekalanos,et al.  Tit-for-Tat: Type VI Secretion System Counterattack during Bacterial Cell-Cell Interactions , 2013, Cell.

[182]  Eric P. Skaar,et al.  Genomic and Functional Analysis of the Type VI Secretion System in Acinetobacter , 2013, PloS one.

[183]  V. Godoy,et al.  Antibiotic Resistance Acquired through a DNA Damage-Inducible Response in Acinetobacter baumannii , 2013, Journal of bacteriology.

[184]  Nicole R. Luke-Marshall,et al.  The K1 Capsular Polysaccharide from Acinetobacter baumannii Is a Potential Therapeutic Target via Passive Immunization , 2013, Infection and Immunity.

[185]  R. Bonomo,et al.  Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes. , 2013, Vaccine.

[186]  Eric P. Skaar,et al.  Identification of an Acinetobacter baumannii Zinc Acquisition System that Facilitates Resistance to Calprotectin-mediated Zinc Sequestration , 2012, PLoS pathogens.

[187]  Ming-Chin Chan,et al.  A Truncated AdeS Kinase Protein Generated by ISAba1 Insertion Correlates with Tigecycline Resistance in Acinetobacter baumannii , 2012, PloS one.

[188]  M. Almuzara,et al.  Emergence and Spread of Plasmid-Borne tet(B)::ISCR2 in Minocycline-Resistant Acinetobacter baumannii Isolates , 2012, Antimicrobial Agents and Chemotherapy.

[189]  A. Rakin,et al.  Hunger for iron: the alternative siderophore iron scavenging systems in highly virulent Yersinia , 2012, Front. Cell. Inf. Microbio..

[190]  M. Adams,et al.  Inhibition of LpxC Protects Mice from Resistant Acinetobacter baumannii by Modulating Inflammation and Enhancing Phagocytosis , 2012, mBio.

[191]  M. Sunbul,et al.  Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii. , 2012, International journal of antimicrobial agents.

[192]  P. Visca,et al.  In Vitro and In Vivo Antimicrobial Activities of Gallium Nitrate against Multidrug-Resistant Acinetobacter baumannii , 2012, Antimicrobial Agents and Chemotherapy.

[193]  F. Kokturk,et al.  Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia , 2012, Epidemiology and Infection.

[194]  K. Seme,et al.  Dissemination of New Delhi metallo-β-lactamase-1-producing Acinetobacter baumannii in Europe. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[195]  S. Kuo,et al.  Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10 years: Nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program , 2012, BMC Infectious Diseases.

[196]  T. Umland,et al.  In Vivo-Validated Essential Genes Identified in Acinetobacter baumannii by Using Human Ascites Overlap Poorly with Essential Genes Detected on Laboratory Media , 2012, mBio.

[197]  P. Higgins,et al.  Molecular Epidemiology of Acinetobacter baumannii Bloodstream Isolates Obtained in the United States from 1995 to 2004 Using rep-PCR and Multilocus Sequence Typing , 2012, Journal of Clinical Microbiology.

[198]  G. Pier,et al.  Evaluation of the Trimeric Autotransporter Ata as a Vaccine Candidate against Acinetobacter baumannii Infections , 2012, Infection and Immunity.

[199]  Rui Wang,et al.  Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. , 2012, The Journal of antimicrobial chemotherapy.

[200]  D. Zurawski,et al.  Extracellular stress and lipopolysaccharide modulate Acinetobacter baumannii surface-associated motility , 2012, Journal of Microbiology.

[201]  Nichollas E. Scott,et al.  Identification of a General O-linked Protein Glycosylation System in Acinetobacter baumannii and Its Role in Virulence and Biofilm Formation , 2012, PLoS pathogens.

[202]  E. Sugawara,et al.  OmpA Is the Principal Nonspecific Slow Porin of Acinetobacter baumannii , 2012, Journal of bacteriology.

[203]  C. Hsiung,et al.  Increase of Carbapenem-Resistant Acinetobacter baumannii Infection in Acute Care Hospitals in Taiwan: Association with Hospital Antimicrobial Usage , 2012, PloS one.

[204]  G. Pier,et al.  Identification of Ata, a Multifunctional Trimeric Autotransporter of Acinetobacter baumannii , 2012, Journal of bacteriology.

[205]  L. Actis,et al.  The Acinetobacter baumannii entA Gene Located Outside the Acinetobactin Cluster Is Critical for Siderophore Production, Iron Acquisition and Virulence , 2012, PloS one.

[206]  F. Luzzaro,et al.  Emergence and spread of a multidrug-resistant Acinetobacter baumannii clone producing both the carbapenemase OXA-23 and the 16S rRNA methylase ArmA. , 2012, Journal of medical microbiology.

[207]  W. Hol,et al.  The type II secretion system: biogenesis, molecular architecture and mechanism , 2012, Nature Reviews Microbiology.

[208]  M. McConnell,et al.  Role of Fibronectin in the Adhesion of Acinetobacter baumannii to Host Cells , 2012, PloS one.

[209]  Samuel M. Greer,et al.  Stress Response and Virulence Functions of the Acinetobacter baumannii NfuA Fe-S Scaffold Protein , 2012, Journal of bacteriology.

[210]  Ayush Kumar,et al.  Growth phase-dependent expression of RND efflux pump- and outer membrane porin-encoding genes in Acinetobacter baumannii ATCC 19606. , 2012, The Journal of antimicrobial chemotherapy.

[211]  K. Ko,et al.  In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin- or tigecycline-resistant isolates. , 2012, Journal of medical microbiology.

[212]  Gilbert GREUB,et al.  Applications of MALDI-TOF mass spectrometry in clinical diagnostic microbiology. , 2012, FEMS microbiology reviews.

[213]  Chul Hee Choi,et al.  Acinetobacter baumannii outer membrane protein a modulates the biogenesis of outer membrane vesicles , 2012, The Journal of Microbiology.

[214]  P. Courvalin,et al.  Expression of the Resistance-Nodulation-Cell Division Pump AdeIJK in Acinetobacter baumannii Is Regulated by AdeN, a TetR-Type Regulator , 2012, Antimicrobial Agents and Chemotherapy.

[215]  Ming-Feng Lin,et al.  Clonal spread of multidrug-resistant Acinetobacter baumannii in eastern Taiwan. , 2012, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[216]  M. Adams,et al.  Active and Passive Immunization Protects against Lethal, Extreme Drug Resistant-Acinetobacter baumannii Infection , 2012, PloS one.

[217]  J. Gaddy,et al.  Role of Acinetobactin-Mediated Iron Acquisition Functions in the Interaction of Acinetobacter baumannii Strain ATCC 19606T with Human Lung Epithelial Cells, Galleria mellonella Caterpillars, and Mice , 2012, Infection and Immunity.

[218]  Naohisa Matsunaga,et al.  [Acinetobacter spp]. , 2012, Nihon rinsho. Japanese journal of clinical medicine.

[219]  S. Pournaras,et al.  Evolution of multidrug-resistant Acinetobacter baumannii clonal lineages: a 10 year study in Greece (2000-09). , 2011, The Journal of antimicrobial chemotherapy.

[220]  J. Pachón,et al.  Attenuated virulence of a slow-growing pandrug-resistant Acinetobacter baumannii is associated with decreased expression of genes encoding the porins CarO and OprD-like. , 2011, International journal of antimicrobial agents.

[221]  S. Ichiyama,et al.  Interspecies dissemination of a novel class 1 integron carrying blaIMP-19 among Acinetobacter species in Japan. , 2011, The Journal of antimicrobial chemotherapy.

[222]  P. Nordmann,et al.  Genetic diversity of carbapenem-hydrolysing β-lactamases in Acinetobacter baumannii from Romanian hospitals. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[223]  P. Nordmann,et al.  Genetic Features of CTX-M-15-Producing Acinetobacter baumannii from Haiti , 2011, Antimicrobial Agents and Chemotherapy.

[224]  P. Nordmann,et al.  Structure-function relationships of CarO, the carbapenem resistance-associated outer membrane protein of Acinetobacter baumannii. , 2011, The Journal of antimicrobial chemotherapy.

[225]  R. Bonomo,et al.  Genetic analysis of surface motility in Acinetobacter baumannii. , 2011, Microbiology.

[226]  J. Kaplan Antibiotic-Induced Biofilm Formation , 2011, The International journal of artificial organs.

[227]  T. Wichelhaus,et al.  Molecular characterization of blaNDM-1 in an Acinetobacter baumannii strain isolated in Germany in 2007. , 2011, The Journal of antimicrobial chemotherapy.

[228]  H. Goossens,et al.  Dissemination of an NDM-2-Producing Acinetobacter baumannii Clone in an Israeli Rehabilitation Center , 2011, Antimicrobial Agents and Chemotherapy.

[229]  M. McConnell,et al.  Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii. , 2011, Vaccine.

[230]  P. Visca,et al.  Deciphering the Multifactorial Nature of Acinetobacter baumannii Pathogenicity , 2011, PloS one.

[231]  Yee-Chun Chen,et al.  Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. , 2011, Diagnostic microbiology and infectious disease.

[232]  K. Garey,et al.  In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. , 2011, The Southeast Asian journal of tropical medicine and public health.

[233]  N. Loman,et al.  Whole-genome comparison of two Acinetobacter baumannii isolates from a single patient, where resistance developed during tigecycline therapy. , 2011, The Journal of antimicrobial chemotherapy.

[234]  L. Dijkshoorn,et al.  Acinetobacter calcoaceticus–Acinetobacter baumannii complex species in clinical specimens in Singapore , 2011, Epidemiology and Infection.

[235]  R. Hancock,et al.  The pmrCAB Operon Mediates Polymyxin Resistance in Acinetobacter baumannii ATCC 17978 and Clinical Isolates through Phosphoethanolamine Modification of Lipid A , 2011, Antimicrobial Agents and Chemotherapy.

[236]  J. Barbé,et al.  Acinetobacter baumannii RecA Protein in Repair of DNA Damage, Antimicrobial Resistance, General Stress Response, and Virulence , 2011, Journal of bacteriology.

[237]  G. Bou,et al.  Multidrug-Resistant Acinetobacter baumannii Harboring OXA-24 Carbapenemase, Spain , 2011, Emerging infectious diseases.

[238]  Ming-Feng Lin,et al.  Molecular epidemiology and antimicrobial resistance determinants of multidrug-resistant Acinetobacter baumannii in five proximal hospitals in Taiwan. , 2011, Japanese journal of infectious diseases.

[239]  N. Woodford,et al.  Phosphoethanolamine Modification of Lipid A in Colistin-Resistant Variants of Acinetobacter baumannii Mediated by the pmrAB Two-Component Regulatory System , 2011, Antimicrobial Agents and Chemotherapy.

[240]  N. Gordon,et al.  In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. , 2011, The Journal of antimicrobial chemotherapy.

[241]  J. Li,et al.  Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients , 2011, BMC infectious diseases.

[242]  N. Soares,et al.  Horizontal Transfer of the OXA-24 Carbapenemase Gene via Outer Membrane Vesicles: a New Mechanism of Dissemination of Carbapenem Resistance Genes in Acinetobacter baumannii , 2011, Antimicrobial Agents and Chemotherapy.

[243]  S. I. Kim,et al.  Carbapenem-resistant Acinetobacter baumannii: diversity of resistant mechanisms and risk factors for infection , 2011, Epidemiology and Infection.

[244]  D. Wareham,et al.  In Vivo Efficacy of Glycopeptide-Colistin Combination Therapies in a Galleria mellonella Model of Acinetobacter baumannii Infection , 2011, Antimicrobial Agents and Chemotherapy.

[245]  I. Goic-Barisic,et al.  Outbreak in Croatia caused by a new carbapenem-resistant clone of Acinetobacter baumannii producing OXA-72 carbapenemase. , 2011, The Journal of hospital infection.

[246]  P. Nordmann,et al.  PER-7, an Extended-Spectrum β-Lactamase with Increased Activity toward Broad-Spectrum Cephalosporins in Acinetobacter baumannii , 2011, Antimicrobial Agents and Chemotherapy.

[247]  Je Chul Lee,et al.  Acinetobacter baumannii Secretes Cytotoxic Outer Membrane Protein A via Outer Membrane Vesicles , 2011, PloS one.

[248]  Ming-Feng Lin,et al.  Emergence and dissemination of blaOXA-23-carrying imipenem-resistant Acinetobacter sp in a regional hospital in Taiwan. , 2011, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[249]  X. H. Liu,et al.  Genet. Mol. Res. , 2011 .

[250]  Yunsong Yu,et al.  Emergence of NDM-1-producing Acinetobacter baumannii in China. , 2011, The Journal of antimicrobial chemotherapy.

[251]  P. Courvalin,et al.  Efflux-Mediated Antibiotic Resistance in Acinetobacter spp , 2010, Antimicrobial Agents and Chemotherapy.

[252]  Mina Kim,et al.  Prevalence and diversity of carbapenemases among imipenem-nonsusceptible Acinetobacter isolates in Korea: emergence of a novel OXA-182. , 2010, Diagnostic microbiology and infectious disease.

[253]  A. Viale,et al.  ISAba825, a Functional Insertion Sequence Modulating Genomic Plasticity and bla OXA-58 Expression in Acinetobacter baumannii , 2010, Antimicrobial Agents and Chemotherapy.

[254]  B. Özbek,et al.  Postantibiotic Effects of Tigecycline, Colistin Sulfate, and Levofloxacin Alone or Tigecycline-Colistin Sulfate and Tigecycline-Levofloxacin Combinations against Acinetobacter baumannii , 2010, Chemotherapy.

[255]  Ronald N. Jones,et al.  Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009). , 2010, Diagnostic microbiology and infectious disease.

[256]  Ming-Feng Lin,et al.  Role of integrons in antimicrobial susceptibility patterns of Acinetobacter baumannii. , 2010, Japanese journal of infectious diseases.

[257]  D. Yong,et al.  A Novel Insertion Sequence, ISAba10, Inserted into ISAba1 Adjacent to the bla OXA-23 Gene and Disrupting the Outer Membrane Protein Gene carO in Acinetobacter baumannii , 2010, Antimicrobial Agents and Chemotherapy.

[258]  P. Krishnan,et al.  Coexistence of blaOXA-23 with blaNDM-1 and armA in clinical isolates of Acinetobacter baumannii from India. , 2010, The Journal of antimicrobial chemotherapy.

[259]  M. Kuehn,et al.  Biological functions and biogenesis of secreted bacterial outer membrane vesicles. , 2010, Annual review of microbiology.

[260]  Jian Li,et al.  Colistin Resistance in Acinetobacter baumannii Is Mediated by Complete Loss of Lipopolysaccharide Production , 2010, Antimicrobial Agents and Chemotherapy.

[261]  D. Gage,et al.  Characterization of a Two-Component Regulatory System That Regulates Succinate-Mediated Catabolite Repression in Sinorhizobium meliloti , 2010, Journal of bacteriology.

[262]  V. Srinivasan,et al.  Molecular and functional characterization of a novel efflux pump, AmvA, mediating antimicrobial and disinfectant resistance in Acinetobacter baumannii. , 2010, The Journal of antimicrobial chemotherapy.

[263]  P. Nordmann,et al.  GES Extended-Spectrum β-Lactamases in Acinetobacter baumannii Isolates in Belgium , 2010, Antimicrobial Agents and Chemotherapy.

[264]  S. Kuo,et al.  Emergence and Distribution of Plasmids Bearing the blaOXA-51-Like Gene with an Upstream ISAba1 in Carbapenem-Resistant Acinetobacter baumannii Isolates in Taiwan , 2010, Antimicrobial Agents and Chemotherapy.

[265]  P. Courvalin,et al.  Overexpression of Resistance-Nodulation-Cell Division Pump AdeFGH Confers Multidrug Resistance in Acinetobacter baumannii , 2010, Antimicrobial Agents and Chemotherapy.

[266]  T. Umland,et al.  The K1 Capsular Polysaccharide of Acinetobacter baumannii Strain 307-0294 Is a Major Virulence Factor , 2010, Infection and Immunity.

[267]  Chul Hee Choi,et al.  Acinetobacter baumannii outer membrane protein a induces dendritic cell death through mitochondrial targeting , 2010, The Journal of Microbiology.

[268]  J. Quinn,et al.  AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. , 2010, The Journal of antimicrobial chemotherapy.

[269]  E. Culebras,et al.  A combination of tigecycline, colistin, and meropenem against multidrug-resistant Acinetobacter baumannii bacteremia in a renal transplant recipient: pharmacodynamic and microbiological aspects. , 2010, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

[270]  A. Koster,et al.  Do Biofilm Formation and Interactions with Human Cells Explain the Clinical Success of Acinetobacter baumannii? , 2010, PloS one.

[271]  S. Amyes,et al.  Characterization of Epidemiologically Unrelated Acinetobacter baumannii Isolates from Four Continents by Use of Multilocus Sequence Typing, Pulsed-Field Gel Electrophoresis, and Sequence-Based Typing of blaOXA-51-like Genes , 2010, Journal of Clinical Microbiology.

[272]  G. Bou,et al.  OXA-24 Carbapenemase Gene Flanked by XerC/XerD-Like Recombination Sites in Different Plasmids from Different Acinetobacter Species Isolated during a Nosocomial Outbreak , 2010, Antimicrobial Agents and Chemotherapy.

[273]  Laura Camarena,et al.  Molecular Mechanisms of Ethanol-Induced Pathogenesis Revealed by RNA-Sequencing , 2010, PLoS pathogens.

[274]  N. Gordon,et al.  Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. , 2010, International journal of antimicrobial agents.

[275]  M. Kuehn,et al.  Virulence and Immunomodulatory Roles of Bacterial Outer Membrane Vesicles , 2010, Microbiology and Molecular Biology Reviews.

[276]  E. Vinogradov,et al.  Identification and Characterization of a Glycosyltransferase Involved in Acinetobacter baumannii Lipopolysaccharide Core Biosynthesis , 2010, Infection and Immunity.

[277]  Eric P. Skaar,et al.  Inactivation of Phospholipase D Diminishes Acinetobacter baumannii Pathogenesis , 2010, Infection and Immunity.

[278]  R. López-Rojas,et al.  Efficacy of tigecycline vs. imipenem in the treatment of experimental Acinetobacter baumannii murine pneumonia , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[279]  M. Tolmasky,et al.  Naturally Competent Acinetobacter baumannii Clinical Isolate as a Convenient Model for Genetic Studies , 2010, Journal of Clinical Microbiology.

[280]  F. Donnarumma,et al.  Molecular Characterization of Acinetobacter Isolates Collected in Intensive Care Units of Six Hospitals in Florence, Italy, during a 3-Year Surveillance Program: a Population Structure Analysis , 2010, Journal of Clinical Microbiology.

[281]  C. Vay,et al.  In vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones. , 2010, Journal of infection in developing countries.

[282]  Ming-Feng Lin,et al.  Distribution of blaOXA-carrying imipenem-resistant Acinetobacter spp. in 3 hospitals in Taiwan. , 2010, Diagnostic microbiology and infectious disease.

[283]  K. Ozdemir,et al.  In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii , 2010, The Journal of Antibiotics.

[284]  C. Dhiraputra,et al.  Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii. , 2010, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[285]  R. López-Rojas,et al.  Efficacy of Rifampin and Its Combinations with Imipenem, Sulbactam, and Colistin in Experimental Models of Infection Caused by Imipenem-Resistant Acinetobacter baumannii , 2010, Antimicrobial Agents and Chemotherapy.

[286]  P. Nordmann,et al.  Worldwide Dissemination of the blaOXA-23 Carbapenemase Gene of Acinetobacter baumannii1 , 2010, Emerging infectious diseases.

[287]  Iraida E. Robledo,et al.  Detection of KPC in Acinetobacter spp. in Puerto Rico , 2009, Antimicrobial Agents and Chemotherapy.

[288]  Eric P. Skaar,et al.  Acinetobacter baumannii Increases Tolerance to Antibiotics in Response to Monovalent Cations , 2009, Antimicrobial Agents and Chemotherapy.

[289]  Jordi Rello,et al.  International study of the prevalence and outcomes of infection in intensive care units. , 2009, JAMA.

[290]  Chul Hee Choi,et al.  Serum resistance of Acinetobacter baumannii through the binding of factor H to outer membrane proteins. , 2009, FEMS microbiology letters.

[291]  N. Prasadarao,et al.  CTX-M β-Lactamase Production and Virulence of Escherichia coli K1 , 2009, Emerging infectious diseases.

[292]  M. S. Ramírez,et al.  Novel Insights about Class 2 Integrons from Experimental and Genomic Epidemiology , 2009, Antimicrobial Agents and Chemotherapy.

[293]  H. Rüden,et al.  Outbreak of carbapenem-resistant Acinetobacter baumannii carrying the carbapenemase OXA-23 in a German university medical centre. , 2009, Journal of medical microbiology.

[294]  A. Papa,et al.  Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in a newly established Greek hospital. , 2009, Microbial drug resistance.

[295]  J. Wu,et al.  A novel aminoglycoside-modifying enzyme gene aac(6')-Ib in a pandrug-resistant Acinetobacter baumannii strain. , 2009, The Journal of hospital infection.

[296]  P. Nordmann,et al.  OXA-143, a Novel Carbapenem-Hydrolyzing Class D β-Lactamase in Acinetobacter baumannii , 2009, Antimicrobial Agents and Chemotherapy.

[297]  V. Srinivasan,et al.  Role of AbeS, a Novel Efflux Pump of the SMR Family of Transporters, in Resistance to Antimicrobial Agents in Acinetobacter baumannii , 2009, Antimicrobial Agents and Chemotherapy.

[298]  H. Kim,et al.  Loss of the 29-kilodalton outer membrane protein in the presence of OXA-51-like enzymes in Acinetobacter baumannii is associated with decreased imipenem susceptibility. , 2009, Microbial drug resistance.

[299]  P. Nordmann,et al.  ISCR2, Another Vehicle for blaVEB Gene Acquisition , 2009, Antimicrobial Agents and Chemotherapy.

[300]  Y. Gho,et al.  Proteome analysis of outer membrane vesicles from a clinical Acinetobacter baumannii isolate. , 2009, FEMS microbiology letters.

[301]  J. Vila,et al.  CraA, a Major Facilitator Superfamily Efflux Pump Associated with Chloramphenicol Resistance in Acinetobacter baumannii , 2009, Antimicrobial Agents and Chemotherapy.

[302]  M. Adams,et al.  Resistance to Colistin in Acinetobacter baumannii Associated with Mutations in the PmrAB Two-Component System , 2009, Antimicrobial Agents and Chemotherapy.

[303]  Chul Hee Choi,et al.  Genetic basis of resistance to aminoglycosides in Acinetobacter spp. and spread of armA in Acinetobacter baumannii sequence group 1 in Korean hospitals. , 2009, Diagnostic microbiology and infectious disease.

[304]  J. Gaddy,et al.  The Acinetobacter baumannii 19606 OmpA Protein Plays a Role in Biofilm Formation on Abiotic Surfaces and in the Interaction of This Pathogen with Eukaryotic Cells , 2009, Infection and Immunity.

[305]  P. Courvalin,et al.  GES-11, a Novel Integron-Associated GES Variant in Acinetobacter baumannii , 2009, Antimicrobial Agents and Chemotherapy.

[306]  P. Nordmann,et al.  Genetic and Biochemical Characterization of the First Extended-Spectrum CARB-Type ß-Lactamase, RTG-4, from Acinetobacter baumannii , 2009, Antimicrobial Agents and Chemotherapy.

[307]  A. Agodi,et al.  Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii strains in intensive care units of multiple Mediterranean hospitals. , 2009, The Journal of antimicrobial chemotherapy.

[308]  N. Gordon,et al.  A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. , 2009, The Journal of antimicrobial chemotherapy.

[309]  N. Woodford,et al.  Diversity of carbapenem resistance mechanisms in Acinetobacter baumannii from a Taiwan hospital: spread of plasmid-borne OXA-72 carbapenemase. , 2009, The Journal of antimicrobial chemotherapy.

[310]  T. Umland,et al.  Penicillin-binding protein 7/8 contributes to the survival of Acinetobacter baumannii in vitro and in vivo. , 2009, The Journal of infectious diseases.

[311]  P. Visca,et al.  Annals of Clinical Microbiology and , 2009 .

[312]  D. Nicolau,et al.  Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. , 2008, The Journal of antimicrobial chemotherapy.

[313]  Ronald N. Jones,et al.  Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. , 2008, The Journal of antimicrobial chemotherapy.

[314]  Jay Steingrub,et al.  International study of the prevalence and outcomes of infection in intensive care units , 2009 .

[315]  P. White,et al.  Antibiotic resistance determinants in nosocomial strains of multidrug-resistant Acinetobacter baumannii. , 2009, The Journal of antimicrobial chemotherapy.

[316]  J. Bartlett,et al.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[317]  Chul Hee Choi,et al.  Acinetobacter baumannii invades epithelial cells and outer membrane protein A mediates interactions with epithelial cells , 2008, BMC Microbiology.

[318]  Yen-Hsu Chen,et al.  Molecular characterisation of the metallo-beta-lactamase genes in imipenem-resistant Gram-negative bacteria from a university hospital in southern Taiwan. , 2008, International journal of antimicrobial agents.

[319]  J. Gaddy,et al.  Characterization of a two-component regulatory system from Acinetobacter baumannii that controls biofilm formation and cellular morphology. , 2008, Microbiology.

[320]  M. Adams,et al.  Comparative Genome Sequence Analysis of Multidrug-Resistant Acinetobacter baumannii , 2008, Journal of bacteriology.

[321]  Jien-Wei Liu,et al.  Antimicrobial effects of varied combinations of meropenem, sulbactam, and colistin on a multidrug-resistant Acinetobacter baumannii isolate that caused meningitis and bacteremia. , 2008, Microbial drug resistance.

[322]  J. Noh,et al.  Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii. , 2008, International journal of antimicrobial agents.

[323]  A. Oliver,et al.  Benefit of Having Multiple ampD Genes for Acquiring β-Lactam Resistance without Losing Fitness and Virulence in Pseudomonas aeruginosa , 2008, Antimicrobial Agents and Chemotherapy.

[324]  Harald Seifert,et al.  Acinetobacter baumannii: Emergence of a Successful Pathogen , 2008, Clinical Microbiology Reviews.

[325]  P. Higgins,et al.  Clonal spread of carbapenem-resistant OXA-23-positive Acinetobacter baumannii in a Bulgarian university hospital. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[326]  Y. Carmeli,et al.  Extended-Spectrum β-Lactamase Production Is Associated with an Increase in Cell Invasion and Expression of Fimbrial Adhesins in Klebsiella pneumoniae , 2008, Antimicrobial Agents and Chemotherapy.

[327]  E. S. Moland,et al.  In Vitro Activity of Tigecycline against Multidrug-Resistant Acinetobacter baumannii and Selection of Tigecycline-Amikacin Synergy , 2008, Antimicrobial Agents and Chemotherapy.

[328]  A. Tsakris,et al.  Clusters of imipenem-resistant Acinetobacter baumannii clones producing different carbapenemases in an intensive care unit. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[329]  F. Fernández,et al.  Tigecycline for Acinetobacter baumannii infection: other considerations. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[330]  Te‐Li Chen,et al.  Acquisition of a Plasmid-Borne blaOXA-58 Gene with an Upstream IS1008 Insertion Conferring a High Level of Carbapenem Resistance to Acinetobacter baumannii , 2008, Antimicrobial Agents and Chemotherapy.

[331]  J. Vila,et al.  Biofilm formation in Acinetobacter baumannii: associated features and clinical implications. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[332]  P. Nordmann,et al.  Carbapenem-Resistant Acinetobacter baumannii Isolates from Tunisia Producing the OXA-58-Like Carbapenem-Hydrolyzing Oxacillinase OXA-97 , 2008, Antimicrobial Agents and Chemotherapy.

[333]  Eric P. Skaar,et al.  Metal Chelation and Inhibition of Bacterial Growth in Tissue Abscesses , 2008, Science.

[334]  D. Linkin,et al.  Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[335]  S. Magnet,et al.  AdeIJK, a Resistance-Nodulation-Cell Division Pump Effluxing Multiple Antibiotics in Acinetobacter baumannii , 2008, Antimicrobial Agents and Chemotherapy.

[336]  C. Qi,et al.  Characterization of Genetic Diversity of Carbapenem-Resistant Acinetobacter baumannii Clinical Strains Collected from 2004 to 2007 , 2008, Journal of Clinical Microbiology.

[337]  M. Bassetti,et al.  Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. , 2007, The Journal of antimicrobial chemotherapy.

[338]  Chul Hee Choi,et al.  Acinetobacter baumannii outer membrane protein A targets the nucleus and induces cytotoxicity , 2007, Cellular microbiology.

[339]  A. Viale,et al.  CarO, an Acinetobacter baumannii outer membrane protein involved in carbapenem resistance, is essential for l‐ornithine uptake , 2007, FEBS letters.

[340]  J. Vila,et al.  High prevalence of carbapenem-hydrolysing oxacillinases in epidemiologically related and unrelated Acinetobacter baumannii clinical isolates in Spain. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[341]  Jian Li,et al.  Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. , 2007, The Journal of antimicrobial chemotherapy.

[342]  P. Nordmann,et al.  Panresistant extended-spectrum beta-lactamase SHV-5-producing Acinetobacter baumannii from New York City. , 2007, The Journal of antimicrobial chemotherapy.

[343]  S. Amyes,et al.  Eleven novel OXA-51-like enzymes from clinical isolates of Acinetobacter baumannii. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[344]  H. Seifert,et al.  Activity of Meropenem with and without Ciprofloxacin and Colistin against Pseudomonas aeruginosa and Acinetobacter baumannii , 2007, Antimicrobial Agents and Chemotherapy.

[345]  C. Murray,et al.  Development of Colistin-Dependent Acinetobacter baumannii-Acinetobacter calcoaceticus Complex , 2007, Antimicrobial Agents and Chemotherapy.

[346]  Qiwen Yang,et al.  Molecular Epidemiology of Clinical Isolates of Carbapenem-Resistant Acinetobacter spp. from Chinese Hospitals , 2007, Antimicrobial Agents and Chemotherapy.

[347]  Wensi S. Hu,et al.  An OXA-66/OXA-51-Like Carbapenemase and Possibly an Efflux Pump Are Associated with Resistance to Imipenem in Acinetobacter baumannii , 2007, Antimicrobial Agents and Chemotherapy.

[348]  Qing Yang,et al.  Widespread occurrence of aminoglycoside resistance due to ArmA methylase in imipenem-resistant Acinetobacter baumannii isolates in China. , 2007, The Journal of antimicrobial chemotherapy.

[349]  Stephen G. J. Smith,et al.  A molecular Swiss army knife: OmpA structure, function and expression. , 2007, FEMS microbiology letters.

[350]  R. Bonomo,et al.  Global Challenge of Multidrug-Resistant Acinetobacter baumannii , 2007, Antimicrobial Agents and Chemotherapy.

[351]  L. Peixe,et al.  Molecular Epidemiology of Imipenem-Resistant Acinetobacter haemolyticus and Acinetobacter baumannii Isolates Carrying Plasmid-Mediated OXA-40 from a Portuguese Hospital , 2007, Antimicrobial Agents and Chemotherapy.

[352]  P. Bradford,et al.  AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex. , 2007, The Journal of antimicrobial chemotherapy.

[353]  D. Paterson,et al.  Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii , 2007, Antimicrobial Agents and Chemotherapy.

[354]  P. Nordmann,et al.  Identification of the Novel Narrow-Spectrum β-Lactamase SCO-1 in Acinetobacter spp. from Argentina , 2007, Antimicrobial Agents and Chemotherapy.

[355]  R. Bonomo,et al.  Spread in an Italian Hospital of a Clonal Acinetobacter baumannii Strain Producing the TEM-92 Extended-Spectrum β-Lactamase , 2007, Antimicrobial Agents and Chemotherapy.

[356]  L. Hsu,et al.  IMP-4 and OXA β-lactamases in Acinetobacter baumannii from Singapore , 2007 .

[357]  Chul Hee Choi,et al.  Differences in phenotypic and genotypic traits against antimicrobial agents between Acinetobacter baumannii and Acinetobacter genomic species 13TU. , 2007, The Journal of antimicrobial chemotherapy.

[358]  Y. Carmeli,et al.  High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. , 2007, The Journal of antimicrobial chemotherapy.

[359]  G. Biancofiore,et al.  Colistin, meropenem and rifampin in a combination therapy for multi-drug-resistant Acinetobacter baumannii multifocal infection. A case report. , 2007, Minerva anestesiologica.

[360]  S. Pournaras,et al.  Identification of a novel bla(OXA-51) variant, bla(OXA-92), from a clinical isolate of Acinetobacter baumannii. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[361]  R. Morgan,et al.  Acinetobacter baumannii lipopolysaccharides are potent stimulators of human monocyte activation via Toll-like receptor 4 signalling. , 2007, Journal of medical microbiology.

[362]  Lu-Cheng Kuo,et al.  Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[363]  P. Nordmann,et al.  Genetics and Expression of the Carbapenem-Hydrolyzing Oxacillinase Gene blaOXA-23 in Acinetobacter baumannii , 2007, Antimicrobial Agents and Chemotherapy.

[364]  F. Romesberg,et al.  Controlling Mutation: Intervening in Evolution as a Therapeutic Strategy , 2007, Critical reviews in biochemistry and molecular biology.

[365]  L. Hsu,et al.  IMP-4 and OXA beta-lactamases in Acinetobacter baumannii from Singapore. , 2007, The Journal of antimicrobial chemotherapy.

[366]  T. Tsaganos,et al.  Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. , 2007, International journal of antimicrobial agents.

[367]  L. Dijkshoorn,et al.  Horizontal Gene Transfer in a Polyclonal Outbreak of Carbapenem-Resistant Acinetobacter baumannii , 2006, Journal of Clinical Microbiology.

[368]  Chieh-Chen Huang,et al.  Predictive biomarkers for drug-resistant Acinetobacter baumannii isolates with bla(TEM-1), AmpC-type bla and integrase 1 genotypes. , 2006, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[369]  B. Charra,et al.  Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. , 2006, The Journal of infection.

[370]  M. Galas,et al.  Emergence of PER-2 and VEB-1a in Acinetobacter baumannii Strains in the Americas , 2006, Antimicrobial Agents and Chemotherapy.

[371]  F. Budak,et al.  High prevalence of OXA-51-type class D beta-lactamases among ceftazidime-resistant clinical isolates of Acinetobacter spp.: co-existence with OXA-58 in multiple centres. , 2006, The Journal of antimicrobial chemotherapy.

[372]  J. Quinn,et al.  Multicity Outbreak of Carbapenem-Resistant Acinetobacter baumannii Isolates Producing the Carbapenemase OXA-40 , 2006, Antimicrobial Agents and Chemotherapy.

[373]  J. Desenclos,et al.  VEB-1 Extended-Spectrum β-lactamase–producing Acinetobacter baumannii, France , 2006, Emerging Infectious Diseases.

[374]  M. Kaufmann,et al.  Identification of Acinetobacter baumannii by Detection of the blaOXA-51-like Carbapenemase Gene Intrinsic to This Species , 2006, Journal of Clinical Microbiology.

[375]  J. Desenclos,et al.  VEB-1 Extended-spectrum beta-lactamase-producing Acinetobacter baumannii, France. , 2006, Emerging infectious diseases.

[376]  Stephen Lory,et al.  A Virulence Locus of Pseudomonas aeruginosa Encodes a Protein Secretion Apparatus , 2006, Science.

[377]  A. Oliver,et al.  OXA-24, a Novel Class D β-Lactamase with Carbapenemase Activity in an Acinetobacter baumannii Clinical Strain , 2006, Antimicrobial Agents and Chemotherapy.

[378]  A. Maniatis,et al.  VIM-1 Metallo-β-lactamase in Acinetobacter baumannii , 2006, Emerging infectious diseases.

[379]  A. Gales,et al.  Dissemination of IMP-1 Metallo-β-Lactamase–Producing Acinetobacter Species in a Brazilian Teaching Hospital , 2006, Infection Control & Hospital Epidemiology.

[380]  P. Higgins,et al.  Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide. , 2006, The Journal of antimicrobial chemotherapy.

[381]  M. Kaufmann,et al.  The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. , 2006, FEMS microbiology letters.

[382]  F. Can,et al.  In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. , 2006, International journal of antimicrobial agents.

[383]  P. Fournier,et al.  The epidemiology and control of Acinetobacter baumannii in health care facilities. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[384]  A. Maniatis,et al.  Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit. , 2006, The Journal of antimicrobial chemotherapy.

[385]  D. Raoult,et al.  Sequencing of the rpoB Gene and Flanking Spacers for Molecular Identification of Acinetobacter Species , 2006, Journal of Clinical Microbiology.

[386]  P. Nordmann,et al.  Cephalosporinase over-expression resulting from insertion of ISAba1 in Acinetobacter baumannii. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[387]  W. Nelson,et al.  Identification of a conserved bacterial protein secretion system in Vibrio cholerae using the Dictyostelium host model system , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[388]  J. Weissenbach,et al.  Comparative Genomics of Multidrug Resistance in Acinetobacter baumannii , 2006, PLoS genetics.

[389]  S. Shoham,et al.  Amikacin and colistin for treatment of Acinetobacter baumannii meningitis. , 2005, The Journal of infection.

[390]  G. Bou,et al.  Cloning and Functional Analysis of the Gene Encoding the 33- to 36-Kilodalton Outer Membrane Protein Associated with Carbapenem Resistance in Acinetobacter baumannii , 2005, Antimicrobial Agents and Chemotherapy.

[391]  D. Vallenet,et al.  Channel Formation by CarO, the Carbapenem Resistance-Associated Outer Membrane Protein of Acinetobacter baumannii , 2005, Antimicrobial Agents and Chemotherapy.

[392]  G. Rossolini,et al.  Novel Acquired Metallo-β-Lactamase Gene, blaSIM-1, in a Class 1 Integron from Acinetobacter baumannii Clinical Isolates from Korea , 2005, Antimicrobial Agents and Chemotherapy.

[393]  J. Chen,et al.  AbeM, an H+-Coupled Acinetobacter baumannii Multidrug Efflux Pump Belonging to the MATE Family of Transporters , 2005, Antimicrobial Agents and Chemotherapy.

[394]  J. Claverie,et al.  Characterization of the Naturally Occurring Oxacillinase of Acinetobacter baumannii , 2005, Antimicrobial Agents and Chemotherapy.

[395]  J. Pagés,et al.  Identification of an OprD homologue in Acinetobacter baumannii. , 2005, Journal of proteome research.

[396]  P. Nordmann,et al.  Outbreak of Carbapenem-Resistant Acinetobacter baumannii Producing the Carbapenemase OXA-23 in a Tertiary Care Hospital of Papeete, French Polynesia , 2005, Journal of Clinical Microbiology.

[397]  E. Nicastri,et al.  Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[398]  Chul Hee Choi,et al.  Outer membrane protein 38 of Acinetobacter baumannii localizes to the mitochondria and induces apoptosis of epithelial cells , 2005, Cellular microbiology.

[399]  P. Nordmann,et al.  Contribution of Acquired Carbapenem-Hydrolyzing Oxacillinases to Carbapenem Resistance in Acinetobacter baumannii , 2005, Antimicrobial Agents and Chemotherapy.

[400]  L. Rice,et al.  Identification of a New Allelic Variant of the Acinetobacter baumannii Cephalosporinase , ADC-7-Lactamase : Defining a Unique Family of Class C Enzymes ‡ , 2005 .

[401]  P. Nordmann,et al.  Genetic Environment and Expression of the Extended-Spectrum β-Lactamase blaPER-1 Gene in Gram-Negative Bacteria , 2005, Antimicrobial Agents and Chemotherapy.

[402]  A. Viale,et al.  Acquisition of Resistance to Carbapenems in Multidrug-Resistant Clinical Strains of Acinetobacter baumannii: Natural Insertional Inactivation of a Gene Encoding a Member of a Novel Family of β-Barrel Outer Membrane Proteins , 2005, Antimicrobial Agents and Chemotherapy.

[403]  M. Vaneechoutte,et al.  Species-Level Identification of Isolates of the Acinetobacter calcoaceticus-Acinetobacter baumannii Complex by Sequence Analysis of the 16S-23S rRNA Gene Spacer Region , 2005, Journal of Clinical Microbiology.

[404]  S. H. Lee,et al.  Investigation of a nosocomial outbreak of Acinetobacter baumannii producing PER-1 extended-spectrum beta-lactamase in an intensive care unit. , 2005, The Journal of hospital infection.

[405]  P. Nordmann,et al.  OXA-58, a Novel Class D β-Lactamase Involved in Resistance to Carbapenems in Acinetobacter baumannii , 2005, Antimicrobial Agents and Chemotherapy.

[406]  G. Reid The importance of guidelines in the development and application of probiotics. , 2005, Current pharmaceutical design.

[407]  S. Amyes,et al.  Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[408]  J. Malone,et al.  Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. , 2004, MMWR. Morbidity and mortality weekly report.

[409]  L. Dijkshoorn,et al.  Diversity of aminoglycoside-resistance genes and their association with class 1 integrons among strains of pan-European Acinetobacter baumannii clones. , 2004, Journal of medical microbiology.

[410]  C. Cabellos,et al.  Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. , 2004, The Journal of antimicrobial chemotherapy.

[411]  J. Pachón,et al.  Activity of Tigecycline (GAR-936) against Acinetobacter baumannii Strains, Including Those Resistant to Imipenem , 2004, Antimicrobial Agents and Chemotherapy.

[412]  P. Higgins,et al.  Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii. , 2004, Journal of Antimicrobial Chemotherapy.

[413]  P. Courvalin,et al.  Expression of the RND-Type Efflux Pump AdeABC in Acinetobacter baumannii Is Regulated by the AdeRS Two-Component System , 2004, Antimicrobial Agents and Chemotherapy.

[414]  Y. Arakawa,et al.  Nosocomial transmission of CTX-M-2 beta-lactamase-producing Acinetobacter baumannii in a neurosurgery ward. , 2004, Journal of clinical microbiology.

[415]  S. Zanetti,et al.  PER-1 type beta-lactamase production in Acinetobacter baumannii is related to cell adhesion. , 2004, Medical science monitor : international medical journal of experimental and clinical research.

[416]  Y. Arakawa,et al.  Spread of Novel Aminoglycoside Resistance Gene aac(6′)-Iad among Acinetobacter Clinical Isolates in Japan , 2004, Antimicrobial Agents and Chemotherapy.

[417]  E. Nelson,et al.  Genetic Environment and Transcription of ampC in an Acinetobacter baumannii Clinical Isolate , 2004, Antimicrobial Agents and Chemotherapy.

[418]  E. Hultén,et al.  Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. , 2004, MMWR. Morbidity and mortality weekly report.

[419]  L. Actis,et al.  Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: involvement of a novel chaperone-usher pili assembly system. , 2003, Microbiology.

[420]  N. Caroff,et al.  AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. , 2003, The Journal of antimicrobial chemotherapy.

[421]  J. Ruiz,et al.  Partial characterization of a transposon containing the tet(A) determinant in a clinical isolate of Acinetobacter baumannii. , 2003, The Journal of antimicrobial chemotherapy.

[422]  D. Landman,et al.  Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[423]  J. Ruiz,et al.  Presence of the Tet M Determinant in a Clinical Isolate of Acinetobacter baumannii , 2003, Antimicrobial Agents and Chemotherapy.

[424]  P. Turner,et al.  The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[425]  D. Rimar,et al.  Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. , 2003, The Journal of hospital infection.

[426]  A. Cheng,et al.  Significance of Genomic DNA Group Delineation in Comparative Studies of Antimicrobial Susceptibility of Acinetobacter spp , 2003, Antimicrobial Agents and Chemotherapy.

[427]  P. Nordmann,et al.  Genetic and Functional Analysis of the Chromosome-Encoded Carbapenem-Hydrolyzing Oxacillinase OXA-40 of Acinetobacter baumannii , 2003, Antimicrobial Agents and Chemotherapy.

[428]  Ronald N. Jones,et al.  Emergence of an IMP-like metallo-enzyme in an Acinetobacter baumannii clinical strain from a Brazilian teaching hospital. , 2003, Diagnostic microbiology and infectious disease.

[429]  J. Rodríguez-Baño,et al.  Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[430]  G. Rossolini,et al.  Molecular characterization of metallo-beta-lactamase-producing Acinetobacter baumannii and Acinetobacter genomospecies 3 from Korea: identification of two new integrons carrying the bla(VIM-2) gene cassettes. , 2002, The Journal of antimicrobial chemotherapy.

[431]  J. Ruiz,et al.  Characterization of an integron carrying a new class D beta-lactamase (OXA-37) in Acinetobacter baumannii. , 2002, Microbial drug resistance.

[432]  S. Magnet,et al.  Resistance-Nodulation-Cell Division-Type Efflux Pump Involved in Aminoglycoside Resistance in Acinetobacter baumannii Strain BM4454 , 2001, Antimicrobial Agents and Chemotherapy.

[433]  A. Yamaguchi,et al.  Novel Macrolide-Specific ABC-Type Efflux Transporter inEscherichia coli , 2001, Journal of bacteriology.

[434]  P. Savelkoul,et al.  Antibiotic Resistance Is a Major Risk Factor for Epidemic Behavior of Acinetobacter baumannii , 2001, Infection Control & Hospital Epidemiology.

[435]  N. Woodford,et al.  IMP-4, a Novel Metallo-β-Lactamase from Nosocomial Acinetobacter spp. Collected in Hong Kong between 1994 and 1998 , 2001, Antimicrobial Agents and Chemotherapy.

[436]  N. Woodford,et al.  Characterization of OXA-25, OXA-26, and OXA-27, Molecular Class D β-Lactamases Associated with Carbapenem Resistance in Clinical Isolates of Acinetobacter baumannii , 2001, Antimicrobial Agents and Chemotherapy.

[437]  K. Towner,et al.  Carriage of class 1 integrons and antibiotic resistance in clinical isolates of Acinetobacter baumannii from northern Spain. , 2001, Journal of medical microbiology.

[438]  G. Bou,et al.  Characterization of a Nosocomial Outbreak Caused by a Multiresistant Acinetobacter baumannii Strain with a Carbapenem-Hydrolyzing Enzyme: High-Level Carbapenem Resistance inA. baumannii Is Not Due Solely to the Presence of β-Lactamases , 2000, Journal of Clinical Microbiology.

[439]  A. Oliver,et al.  OXA-24, a Novel Class D β-Lactamase with Carbapenemase Activity in an Acinetobacter baumanniiClinical Strain , 2000, Antimicrobial Agents and Chemotherapy.

[440]  G. Cornaglia,et al.  Characterization of the Metallo-β-Lactamase Determinant of Acinetobacter baumannii AC-54/97 Reveals the Existence of blaIMP Allelic Variants Carried by Gene Cassettes of Different Phylogeny , 2000, Antimicrobial Agents and Chemotherapy.

[441]  G. Bou,et al.  Cloning, Nucleotide Sequencing, and Analysis of the Gene Encoding an AmpC β-Lactamase in Acinetobacter baumannii , 2000, Antimicrobial Agents and Chemotherapy.

[442]  L R Bernstein,et al.  Mechanisms of therapeutic activity for gallium. , 1998, Pharmacological reviews.

[443]  C. Vandenbroucke-Grauls,et al.  Comparison of Amplified Ribosomal DNA Restriction Analysis, Random Amplified Polymorphic DNA Analysis, and Amplified Fragment Length Polymorphism Fingerprinting for Identification ofAcinetobacter Genomic Species and Typing ofAcinetobacter baumannii , 1998, Journal of Clinical Microbiology.

[444]  J. Barr,et al.  In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. , 1998, The Journal of antimicrobial chemotherapy.

[445]  J. Ruiz,et al.  Cloning and nucleotide sequence analysis of a gene encoding an OXA-derived beta-lactamase in Acinetobacter baumannii , 1997, Antimicrobial agents and chemotherapy.

[446]  J. Songer,et al.  Bacterial phospholipases and their role in virulence. , 1997, Trends in microbiology.

[447]  M. Kaufmann,et al.  Comparison of outbreak and nonoutbreak Acinetobacter baumannii strains by genotypic and phenotypic methods , 1996, Journal of clinical microbiology.

[448]  E Bergogne-Bérézin,et al.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features , 1996, Clinical microbiology reviews.

[449]  J. Ruiz,et al.  Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii , 1995, Antimicrobial agents and chemotherapy.

[450]  P. Courvalin,et al.  Detection of aac(6')-I genes in amikacin-resistant Acinetobacter spp. by PCR , 1994, Antimicrobial Agents and Chemotherapy.

[451]  K. Lewis,et al.  Emr, an Escherichia coli locus for multidrug resistance. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[452]  W. Opferkuch,et al.  Imipenem resistance in Acinetobacter baumanii is due to altered penicillin-binding proteins. , 1991, Chemotherapy.